<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768690</url>
  </required_header>
  <id_info>
    <org_study_id>M10-687</org_study_id>
    <nct_id>NCT00768690</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine multiple dose safety, tolerability and
      pharmacokinetics of ABT-333 under nonfasting conditions in healthy adult subjects, and to
      determine the effect of single dose administration of ketoconazole on steady state ABT-333
      pharmacokinetics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, Blinded, Randomized, Placebo-controlled Study in Healthy Adult Subjects to Evaluate
      the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-333
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of pharmacokinetic results.</measure>
    <time_frame>Approximately 1 week.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.</measure>
    <time_frame>Approximately 1 week.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of single dose administration of ketoconazole on steady state ABT-333 pharmacokinetics.</measure>
    <time_frame>Approximately 1 week.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 600mg ABT-333 or placebo, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*
*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>Tablet, see arms for intervention description</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Main Selection Criteria for Healthy Volunteers:

               -  Subject has provided written consent.

               -  Subject is in general good health.

          -  If female, subject is postmenopausal for at least 2 years or surgically sterile.

          -  If female, subject is not pregnant and is not breast-feeding.

          -  Male or female between 18 and 55 years old, inclusive.

          -  If male, subject must be surgically sterile or practicing at least 1 method of birth
             control.

          -  Body Mass Index (BMI) is 18 to 29, inclusive.

        Exclusion Criteria:

          -  See above for main selection criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12701</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD/Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

